Abstract
Purpose Prostate adenocarcinoma frequently metastasizes to bone and is detected via computed tomography (CT) scans. Accurate detection and segmentation of these lesions are critical for diagnosis, prognosis, and monitoring. This study aims to automate lesion detection and segmentation using deep learning models.
Methods and Materials We evaluated several deep learning models for lesion detection (EfficientNet, ResNet34, DenseNet) and segmentation (nnUNetv2, UNet, ResUNet, ResAttUNet). Performance metrics included F1 score, precision, recall, Area Under the Curve (AUC), and Dice Similarity Coefficient (DSC). Pairwise t-tests compared segmentation accuracy. Additionally, we conducted radiomic analyses to compare lesions segmented by deep learning to manual segmentations
Results EfficientNet achieved the highest detection performance, with an F1 score of 0.82, precision of 0.88, recall of 0.79, and AUC of 0.71. Among segmentation models, nnUNetv2 performed best, achieving a DSC of 0.74, with precision and recall values of 0.73 and 0.83, respectively. Pairwise t-tests showed that nnUNetv2 outperformed ResAttUNet, ResUNet, and UNet in segmentation accuracy (p < 0.01). Clinically, nnUNetv2 also demonstrated superior specificity for lesion detection (0.9) compared to the other models. All models performed similarly in distinguishing diffuse and focal lesions, predicting weight-bearing lesions, and identifying lesion locations, although nnUNetv2 had higher specificity for these tasks. Sensitivity was highest for rib lesions and lowest for spine lesions across all models.
Conclusions EfficientNet and nnUNetv2 were the top-performing models for detection and segmentation, respectively. The radiomic features derived from deep learning-based segmentations were comparable to those from manual segmentations, supporting the clinical applicability of these methods. Further analysis of lesion detection and spatial distribution, as well as lesion quality differentiation, underscores the models’ potential for improving diagnostic workflows and patient outcomes in clinical settings.
Competing Interest Statement
Vinay Duddalwar does consulting work with Radmetrix, Roche, Deeptek. We have no conflicts of interests to disclose. Amir Goldkorn has received support or honoraria from OncoSet conference (Northwestern University) and Roswell Park grant rounds (Roswell Park); and has a leadership role on the Norris Comprehensive Cancer Center Executive Committee, SWOG GU Executive Committee, and NIH CONC Study Section.
Funding Statement
Joseph Rich received an RSNA medical student grant in 2023. Vinay Duddalwar received a Ming Hsieh Foundation Grant for this project, as well as additional grants from Samsung Healthcare and Mann Foundation. Amir Goldkorn is funded by NIH grants NIH 5R01CA257610-04, NIH 1R21CA267849-01, NIH F30CA257401-04, and a Wright Foundation Award.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the University of Southern California gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Indicates co-first authorship
Data Availability Statement
Research data are not available at this time.
